Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 2
2018 pubmed 13 citations

Activity of antimicrobial peptides and conventional antibiotics against superantigen positive <i>Staphylococcus aureus</i> isolated from patients with atopic dermatitis.

B&#x142;a&#x17c;ewicz. Izabela I; Ja&#x15b;kiewicz. Maciej M; Piechowicz. Lidia L; Neubauer. Damian D; Nowicki. Roman J RJ; Kamysz. Wojciech W; Bara&#x144;ska-Rybak. Wioletta W

Key Findings

  • S. aureus was found on the skin or nose of most eczema patients (≈75%).
  • High resistance rates were seen for ampicillin, daptomycin, lincomycin and erythromycin among the isolates.
  • LL‑37 and other tested antimicrobial peptides showed similar activity against all strains, with no clear advantage over each other.
  • MRSA strains produced fewer toxins (pvl, eta, seb) than MSSA strains, which produced a broader toxin set.

Practical Outcomes

  • LL‑37 isn’t a standout cure for Staph infections in eczema, so biohackers shouldn’t expect dramatic benefits from using it alone. Focus on proven hygiene, skin barrier support, and monitoring antibiotic resistance rather than relying on peptide supplements. No dosing guidance emerges from this study.

Summary

Researchers looked at skin bacteria from eczema patients and tested both regular antibiotics and natural antimicrobial peptides like LL‑37. They found lots of Staph bacteria, many were resistant to common drugs, and the peptides didn’t work much better or worse across different bacterial strains.

Abstract

<i>Staphylococcus aureus</i> causes a diverse array of diseases, ranging from relatively harmless localized skin infections to life-threatening systemic conditions. It secretes toxins directly associated with particular disease symptoms. To determine the prevalence of methicillin-resistant <i>S. aureus</i> (MRSA) and methicillin-susceptible <i>S. aureus</i> (MSSA) colonization among patients with atopic dermatitis and to assess the antimicrobial susceptibility to conventional antibiotics and selected antimicrobial peptides among toxin-producing strains and nonproducing strains. One hundred patients with atopic dermatitis and 50 healthy people were microbiologically assessed for the carriage of <i>S. aureus</i>. Antimicrobial susceptibility tests were performed using the broth microdilution method for conventional antibiotics and antimicrobial peptides (CAMEL, Citropin 1.1, LL-37, Temporin A). Detection of genes <i>lukS/lukF-PV</i>, <i>tst</i>, <i>sea</i>-<i>sed</i>, <i>eta</i> and <i>etb</i> by multiplex PCR was performed. <i>Staphylococcus aureus</i> strains were isolated from the majority of patients, from either the skin (75%) or the anterior nares (73%). Among the conventional antibiotics tested, the highest rates of resistance were observed for ampicillin, daptomycin, lincomycin and erythromycin. Antimicrobial peptides did not show significant diversity in activity. Among MSSA strains greater differentiation of secreted toxins was observed (<i>sec</i>, <i>eta</i>, <i>pvl</i>, <i>tsst</i>, <i>etb</i>, <i>seb</i>), while in the group of MRSA strains secretion of 3 toxins (<i>pvl</i>, <i>eta</i>, <i>seb</i>) was noted. Antimicrobial resistance continues to evolve. It is important to monitor <i>S. aureus</i> infections. The profile of toxins produced by <i>S. aureus</i> strains is an important consideration in the selection of an antimicrobial agent to treat infections.

Study Information

Provider

pubmed

Year

2018

Date

2018-02-20T00:00:00.000Z

DOI

10.5114/ada.2018.62141

Citations

13

References

50